No matching items found
SHOWING 2 Results
Novartis is buying dry-eye medicine brand ‘Xiidra’ from Takeda Pharmaceutical for up to $5.3 billion as the Swiss pharma-maker refreshes its ophthalmic medicines portfolio with a potential blockbuster. The deal calls for $3.4 billion up front and milestone payments up to $1.9 billion, Novartis said.
Despite strong legislations, India still grapples with the malaise of counterfeit medicines being sold in the open market and online. In fact I recently came across a report which said that about 20 per cent of the drugs manufactured in India are adulterated. It is an unhealthy prognosis but apart from that India